Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Revenue (2021 - 2025)

Kiniksa Pharmaceuticals International's Revenue history spans 5 years, with the latest figure at $202.1 million for Q4 2025.

  • For Q4 2025, Revenue rose 64.95% year-over-year to $202.1 million; the TTM value through Dec 2025 reached $677.6 million, up 60.09%, while the annual FY2025 figure was $677.6 million, 60.09% up from the prior year.
  • Revenue reached $202.1 million in Q4 2025 per KNSA's latest filing, up from $180.9 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $202.1 million in Q4 2025 to a low of -$148.3 million in Q4 2022.
  • Average Revenue over 5 years is $74.7 million, with a median of $79.9 million recorded in 2024.
  • The largest YoY upside for Revenue was 719.64% in 2022 against a maximum downside of 891.12% in 2022.
  • A 5-year view of Revenue shows it stood at $18.7 million in 2021, then plummeted by 891.12% to -$148.3 million in 2022, then skyrocketed by 156.24% to $83.4 million in 2023, then soared by 46.93% to $122.5 million in 2024, then skyrocketed by 64.95% to $202.1 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Revenue are $202.1 million (Q4 2025), $180.9 million (Q3 2025), and $156.8 million (Q2 2025).